Ouro Medicines

Ouro Medicines is a clinical-stage biotechnology company based in South San Francisco, California, defining the future of treatment for people with immune-mediated diseases. Its pipeline centers on T cell engager programs for autoimmune conditions, including the lead candidate OM336 (evaluated in the AIC-1001 clinical trial), alongside an expanded access policy. The company was surfaced as a portfolio company of Norwest Venture Partners and added to the API Evangelist network as a lead. As a therapeutics developer, Ouro Medicines publishes a corporate and scientific website but no public developer program, API, or technical documentation surface. Recent company news includes a definitive agreement for Gilead Sciences to acquire Ouro Medicines to advance its first-in-class T cell engager program for autoimmune diseases.

Ouro Medicines is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Immunology, and Immune-Mediated Diseases.

Ouro Medicines’ developer surface includes engineering blog and 2 more developer resources.

🌐 Visit website 📡 Source on GitHub

3.8/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0

0 APIs

Company Biotechnology Pharmaceuticals ImmunologyImmune-Mediated DiseasesAutoimmune DiseasesClinical Trials Life Sciences Therapeutics

Kin Score

Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0

Composite quality — 3.8/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.4 / 17

Access Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 1.1 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/ouromedicines: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Company 2

The organization behind the API

Website

Website

Blog

Blog

Source (apis.yml)

aid: ouromedicines
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/ouromedicines.png
name: Ouro Medicines
description: Ouro Medicines is a clinical-stage biotechnology company based in South San Francisco, California, defining the
  future of treatment for people with immune-mediated diseases. Its pipeline centers on T cell engager programs for autoimmune
  conditions, including the lead candidate OM336 (evaluated in the AIC-1001 clinical trial), alongside an expanded access
  policy. The company was surfaced as a portfolio company of Norwest Venture Partners and added to the API Evangelist network
  as a lead. As a therapeutics developer, Ouro Medicines publishes a corporate and scientific website but no public developer
  program, API, or technical documentation surface. Recent company news includes a definitive agreement for Gilead Sciences
  to acquire Ouro Medicines to advance its first-in-class T cell engager program for autoimmune diseases.
url: https://raw.githubusercontent.com/api-evangelist/ouromedicines/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- norwest-venture-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Immunology
- Immune-Mediated Diseases
- Autoimmune Diseases
- Clinical Trials
- Life Sciences
- Therapeutics
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/ouromedicines-domain-security.yml
- type: Website
  url: https://ouromedicines.com
- type: Blog
  url: https://ouromedicines.com/news/
x-enrichment:
  date: '2026-07-20'
  status: minimal
  artifacts_added: 1
  pass: local-v1

Ouro Medicines

Kin Score

Security Posture 1

Ouromedicines Domain Security

Resources

Access & Security 1

Company 2

Source (apis.yml)